Summary of Moderna, Inc. R&D Day and Business Updates (September 13, 2023) Company Overview - **Company**: Moderna, Inc. (NASDAQ:MRNA) - **Participants**: Key executives including CEO Stephane Bancel, President Stephen Hoge, and others involved in various therapeutic areas and vaccine programs [2][4] Core Industry Insights - **Industry**: Biotechnology and Pharmaceuticals, focusing on mRNA technology for vaccines and therapeutics - **Key Focus Areas**: Infectious diseases, cancer therapeutics, rare diseases, and vaccine development Key Points and Arguments 1. **Platform Technology**: Moderna's mRNA technology is viewed as a powerful platform for developing a new class of medicines, allowing for high productivity in R&D and capital efficiency [4][5][6][7] 2. **Product Pipeline**: The company aims to launch up to 15 products in the next five years, with a focus on infectious disease vaccines, cancer therapeutics, and rare diseases [12][29] 3. **Positive Phase 3 Data**: Moderna has achieved positive Phase 3 data for COVID-19, RSV, and flu vaccines, demonstrating the effectiveness of its platform [9][19] 4. **Cancer Therapeutics**: The company is advancing its individualized neoantigen therapy for melanoma and has plans for accelerated approval discussions based on promising data [10][15][31] 5. **Vaccine Development**: Moderna is working on next-generation COVID vaccines and combination vaccines (COVID + flu), with clinical data expected soon [13][38] 6. **Regulatory Approvals**: The company has received FDA approval for its updated COVID vaccine and is in discussions for its flu vaccine [44][60] Additional Important Content 1. **Investment in Science**: Moderna emphasizes continuous investment in scientific research to expand the capabilities of its mRNA platform [8][22] 2. **Diverse Applications**: The company is exploring various applications in oncology and rare diseases, including partnerships for gene editing technologies [26][27][23] 3. **Clinical Trials**: Ongoing clinical trials are crucial for validating the safety and efficacy of new vaccines and therapeutics, with a focus on both adult and pediatric populations [39][63] 4. **Monitoring Variants**: Moderna has established a robust process for monitoring COVID-19 variants and updating vaccines accordingly, ensuring continued efficacy against emerging strains [45][56] 5. **Safety Profiles**: The safety profiles of new vaccines are being closely monitored, with data showing acceptable reactogenicity compared to standard vaccines [63][64] Conclusion Moderna is positioned as a leader in the biotechnology sector, leveraging its mRNA platform to develop a wide range of vaccines and therapeutics. The company is focused on expanding its product pipeline, achieving regulatory approvals, and continuously improving its technology to meet public health needs.

Moderna, Inc. (NASDAQ:MRNA) Morgan Stanley 21st Annual Global Healthcare Conference September 12, 2023 12:15 PM ET Company Participants Stephane Bancel - CEO Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Great. Well, good afternoon, everybody. Thanks for joining us. I???m Terence Flynn, the U.S. biopharm analyst at Morgan Stanley. We???re very pleased to be hosting Moderna this afternoon. We have Stephane Bancel, who is the Company???s CEO, Stephane, thanks so much for being here ...

Second Quarter 2023 Financial Results moderr l Financial figures in this presentation as of, and for the quarterly periods ended, June 30, 2023, and June 30, 2022, are unaudited. 2 2Q23 earnings call agenda R&D/Clinical Programs Stephen Hoge, M.D., President Financials Jamey Mock, CFO 3 2Q23 financial highlights Net income (loss): $(1.4) billion Reinvest in the business • $0.2 billion capital expenditures Return capital to shareholders 2Q 2023 Update| Business Review • Submitted updated COVID-19 vaccine to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38753 Moderna, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 81-3467528 (State or Other Jurisdiction of ...

Summary of Moderna, Inc. Conference Call Company Overview - **Company**: Moderna, Inc. (NASDAQ:MRNA) - **Event**: Goldman Sachs 44th Annual Global Healthcare Conference - **Date**: June 14, 2023 - **Participants**: Jamey Mock (CFO), Lavina Talukdar (Head of IR), Salveen Richter (Goldman Sachs Analyst) Key Points Industry and Market Dynamics - Transition from pandemic to endemic is impacting volume predictability and cost of goods sold (COGS) [3][4] - COGS is expected to decrease from 35%-40% to a long-term range of 20%-25% as the market stabilizes [5] - The U.S. COVID vaccine market is projected to be a 100 million dose market in 2023, with a gross price of approximately $129 per dose [23][24] Financial Guidance and Cash Deployment - Moderna has over $16 billion in cash, with plans to invest approximately $7 billion in 2023, including $4.5 billion in R&D [6][8] - Focus areas for R&D include respiratory diseases, manufacturing sciences, and new mechanisms of action [9][10] - Share buybacks have totaled $4.7 billion, with $2.3 billion remaining [9] COVID-19 Vaccine Sales and Market Strategy - Confidence in achieving a minimum of $5 billion in COVID vaccine sales, with $2 billion already delivered in the first half of 2023 [11][12] - Additional orders expected from long-term partners in the UK, Canada, and Switzerland [12][13] - Low probability of entering the Chinese market for COVID vaccines in 2023, but long-term potential exists for other therapeutic areas [15] Competitive Landscape and Opportunities - Positive outlook for gaining market share in the EU following Pfizer's contract reduction [17] - Ongoing negotiations for commercial orders in the U.S. and potential for additional government contracts [19][20] Future Product Pipeline - Respiratory sales projected to reach $8 billion to $15 billion by 2027, with a total addressable market (TAM) of approximately $30 billion for COVID, flu, and RSV combined [25][26] - Focus on combination vaccines to increase market share and vaccination rates [28] - Anticipated commercial launch of RSV vaccine in 2024, with a strong product profile expected to capture market share [29] Research and Development Focus - 48 drugs currently in the pipeline, with significant investment in respiratory and oncology therapies [10][36] - Ongoing studies in latent viruses and rare diseases, with promising data emerging from clinical trials [44][46] Company Transformation and AI Integration - Moderna aims to build a digital-first company, embedding AI and machine learning into all functions [60][61] - The company is focused on creating a different organizational culture and structure compared to traditional large pharmaceutical companies [60] Additional Insights - The company is committed to fiscal prudence while investing in long-term growth opportunities [50][51] - Smaller business development transactions are seen as strategic, with potential for significant value creation in the near future [54][55] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Moderna's focus on innovation, market adaptation, and financial discipline.

Moderna, Inc. (NASDAQ:MRNA) Jefferies Global Healthcare Conference June 8, 2023 10:30 AM ET Company Participants Stephen Hoge - President Conference Call Participants Michael Yee - Jefferies Michael Yee Well, thank you, everyone, for joining us on our next session up here. I think our next guest needs no introduction. He's the President of Moderna, Stephen Hoge. It's good to be here with you. We just came away from ASCO. So, there's some cancer topics to discuss. I'm sure the audience would love to start of ...

Moderna, Inc. (NASDAQ:MRNA) ASCO Investor Event Conference Call June 5, 2023 7:00 PM ET Company Participants Lavina Talukdar - Senior Vice President and Head of Investor Relations Stephen Hoge - President Kyle Holen - Senior Vice President and Head of Development, Therapeutics and Oncology Conference Call Participants Edward Tenthoff - Piper Sandler & Co. Tyler Van Buren - Cowen and Company, LLC Mani Foroohar - SVB Securities LLC Luca Issi - RBC Capital Markets Gena Wang - Barclays Bank plc Michael Yee - Je ...

Moderna, Inc. (NASDAQ:MRNA) Q1 2023 Results Conference Call May 4, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head, Investor Relations Stephane Bancel - Chief Executive Officer Stephen Hoge - President Arpa Garay - Chief Commercial Officer Jamey Mock - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Salveen Richter - Goldman Sachs Tara Bancroft - with TD Cowen Michael Yee - Jefferies Terence Flynn - Morgan Stanley Jessica Fye - JPMorgan Ellie Merle - UBS Luca Issi - RBC ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38753 Moderna, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 81-3467528 (State or Other Jurisdiction o ...

Moderna, Inc. (NASDAQ:MRNA) Cowen 43rd Annual Healthcare Conference Call March 6, 2023 9:10 AM ET Company Participants Stephen Hoge - President Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren Okay. Great. Well, let's go ahead and keep going. Good morning, everyone. It's Tyler Van Buren here, senior biotech analyst at TD Cowen. For this first fireside chat, it's my pleasure to introduce Stephen Hoge, President of Moderna. Thank you very much for being here, Stephen. Stephen Hoge Thank ...